Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
AssigneesPurdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
InventorsCurtis Wright, Benjamin Oshlack, Christopher Breder
Life of this patent
Estimating the term…
Abstract
Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
Claims31
1-40. (canceled)
A pharmaceutical dosage form comprising:
- a mixture comprising (i) buprenorphine or a pharmaceutically acceptable salt thereof;
- (ii) naloxone or a pharmaceutically acceptable salt thereof;
- and
- (iii) a gelling agent comprising polyethylene oxide, the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;
- the dosage form providing an immediate release upon administration to a human patient.
A pharmaceutical dosage form comprising:
- a mixture comprising (i) buprenorphine or a pharmaceutically acceptable salt thereof;
- (ii) naloxone or a pharmaceutically acceptable salt thereof;
- and
- (iii) a gelling agent comprising polyethylene oxide, hydroxypropylmethylcellulose and sugar derived alcohol;
- the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;
- the dosage form providing an immediate release upon administration to a human patient.
A pharmaceutical dosage form comprising:
- a mixture comprising (i) buprenorphine hydrochloride;
- (ii) naloxone hydrochloride;
- and
- (iii) a gelling agent comprising polyethylene oxide, hydroxypropylmethylcellulose and sugar derived alcohol;
- the gelling agent in an effective amount to impart a viscosity of at least about 10 cP when the dosage form is subjected to tampering by dissolution in from about 0.5 to about 10 ml of an aqueous liquid;
- the dosage form providing an immediate release upon administration to a human patient.
Dependencies are inferred from the claim text.